Navigation Links
Healthcare Companies Report Stock Price Updates, and Medical System Integration - Research Report on Johnson & Johnson, Geron, Ligand Pharmaceuticals, Masimo, and Capital Senior Living
Date:12/10/2013

NEW YORK, December 10, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Johnson & Johnson (NYSE: JNJ), Geron Corporation (NASDAQ: GERN), Ligand Pharmaceuticals Inc. (NASDAQ: LGND), Masimo Corporation (NASDAQ: MASI), and Capital Senior Living Corp. (NYSE: CSU). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On December 5, 2013, Johnson & Johnson's stock ended the day's trading at $92.97, reflecting a decrease of 0.70% from the previous closing price. The Company's stock edged down by 1.39% over the past three trading days, compared to the Dow Jones Industrial Average Index which ended 1.17% lower during the same trading period. The Full Research Report on Johnson & Johnson - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/07a8_JNJ

--

Geron Corporation Research Report

On December 5, 2013, Geron Corporation's (Geron) stock gained 2.26% as it closed the day's trading session at $5.87. For the past three trading days, the Company's stock increased 2.44%, compared to the Dow Jones Industrial Average Index which ended 1.17% lower over the same three trading days. The Full Research Report on Geron Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/1ca9_GERN

--

Ligand Pharmaceuticals Inc. Research Report

On December 5, 2013, Ligand Pharmaceuticals Inc.'s (Ligand Pharmaceuticals) stock increased 2.52%, closing the day's trading at $56.52. The Company's stock, however, declined 0.16% over the past three trading days, compared to the Nasdaq Composite Index which ended 0.30% lower during the same trading period. The Full Research Report on Ligand Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3b8d_LGND

--

Masimo Corporation Research Report

On November 22, 2013, Masimo Corporation (Masimo) announced that ACUTRONIC Medical Systems AG has integrated Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry into ACUTRONIC's fabian HFO Neonatal Critical Care Ventilator for improved patient outcomes. According to the Company, the combined technology platform will optimize patient assessments and improve workflow, which allows clinicians to spend more time tending to patients. Masimo's President of Worldwide OEM Business & Corporate Development, Rick Fishel, stated, "The synergies realized between our companies and products support Masimo's mission to improve patient outcomes and reduce the cost of care by taking noninvasive monitoring to new sites and applications. We are very pleased that Masimo's SET® Pulse Oximetry platform is a key component in ACUTRONIC's new neonatal ventilators." The Full Research Report on Masimo Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/6e22_MASI

--

Capital Senior Living Corp. Research Report

On December 5, 2013, Capital Senior Living Corp.'s (Capital Senior Living) stock gained 4.55%, closing the day's trading at $23.42. For the past three trading days, the Company's stock increased 4.46%, compared to the Dow Jones Industrial Average Index which ended 1.17% lower over the same trading period. The Full Research Report on Capital Senior Living Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ca95_CSU

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsCorner.com

 


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals to Present at the 24th Annual Oppenheimer Healthcare Conference
2. New Data Detailing Economic Impact of IV Acetaminophen in Treating Acute Pain to be Presented at Two Major Healthcare Conferences
3. Exel White Paper Identifies Need for Resilience and Reinvented Supply Chain in Life Sciences and Healthcare Industry
4. Atonomics and OMRON Healthcare Enter Agreement for Equity Investment
5. Nora Therapeutics Announces New Time for Presentation at the Oppenheimer 24th Annual Healthcare Conference
6. HeartWare Presentation At The Oppenheimer 24th Annual Healthcare Conference To Be Webcast
7. Questcor Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
8. Amgen To Present At The Oppenheimer 24th Annual Healthcare Conference
9. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
10. Rigel to Present at Oppenheimer Healthcare Conference
11. Omeros to Present at Oppenheimer 24th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 2016 Interview ... Sanofi, leader mondial et diversifié ... pour le premier trimestre 2016. Le ... commente les résultats du premier trimestre ... le reste de l,année. ...
(Date:4/28/2016)... , April 28, 2016  While Abbott,s ... complement the company,s valve repair and stent business, ... also places Abbott more firmly into patient monitoring.  ... the fastest growing device areas, with double-digit growth ... recent report,  Advanced Remote Patient Monitoring ...
(Date:4/28/2016)... , April 28, 2016  The blood testing ... million dollars, according to Kalorama Information and The Freedonia ... immunoassays and nucleic acid testing.  The healthcare research firm ... progress in developing blood collection stations and in improving ... in Kalorama Information,s report, Blood Testing Market ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding its ... following programs will be expanding due to high demand: Master of Business Administration (MBA), ... begin this summer. , School of Business Graduate Program Chair Dr. Ray ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Council for Graduate Medical Education (ACGME) that it has received accreditation for its ... accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics and ...
(Date:4/29/2016)... ... 29, 2016 , ... On Tuesday, April 26, 2016 members of the HomeTown ... of Gov. Nathan Deal on SB 258, the “Rural Health Care Relief” Bill. , ... 70% tax credit to individuals and corporations which donate directly to a “rural hospital” ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... student loans more flexibility in repaying their loans, more information about their loan ... time when total outstanding student loan debt, including federal and private loans, has ...
(Date:4/29/2016)... ... 29, 2016 , ... A new study by a Johns ... hernia have better survival rates if surgery is performed early. Approximately one in ... diaphragm fails to form completely, letting abdominal organs into the chest cavity and ...
Breaking Medicine News(10 mins):